



# Genetic crosses within and between species of *Cryptosporidium*

Sebastian Shaw<sup>a</sup> , Ian S. Cohn<sup>a</sup> , Rodrigo P. Baptista<sup>b</sup> , Guoqin Xia<sup>c</sup> , Bruno Melillo<sup>c,d</sup>, Fiifi Agyabeng-Dadzie<sup>e</sup>, Jessica C. Kissinger<sup>e,f</sup> , and Boris Striepen<sup>a,1</sup>

Edited by Margaret Phillips, The University of Texas Southwestern Medical Center, Dallas, TX; received August 4, 2023; accepted November 12, 2023

Parasites and their hosts are engaged in reciprocal coevolution that balances competing mechanisms of virulence, resistance, and evasion. This often leads to host specificity, but genomic reassortment between different strains can enable parasites to jump host barriers and conquer new niches. In the apicomplexan parasite *Cryptosporidium*, genetic exchange has been hypothesized to play a prominent role in adaptation to humans. The sexual lifecycle of the parasite provides a potential mechanism for such exchange; however, the boundaries of *Cryptosporidium* sex are currently undefined. To explore this experimentally, we established a model for genetic crosses. Drug resistance was engineered using a mutated phenylalanyl tRNA synthetase gene and marking strains with this and the previously used Neo transgene enabled selection of recombinant progeny. This is highly efficient, and genomic recombination is evident and can be continuously monitored in real time by drug resistance, flow cytometry, and PCR mapping. Using this approach, multiple loci can now be modified with ease. We demonstrate that essential genes can be ablated by crossing a Cre recombinase driver strain with floxed strains. We further find that genetic crosses are also feasible between species. Crossing *Cryptosporidium parvum*, a parasite of cattle and humans, and *Cryptosporidium tyzzeri* a mouse parasite resulted in progeny with a recombinant genome derived from both species that continues to vigorously replicate sexually. These experiments have important fundamental and translational implications for the evolution of *Cryptosporidium* and open the door to reverse- and forward-genetic analysis of parasite biology and host specificity.

parasite | diarrheal disease | Apicomplexa | sex | genetic cross

The gastrointestinal parasite *Cryptosporidium* is a leading cause of diarrheal disease around the world and responsible for frequent waterborne outbreaks in the United States (1, 2). *Cryptosporidium* is an AIDS-defining opportunistic infection and a severe threat to immunocompromised individuals (3). While the disease is typically self-limiting in healthy adults, more recent epidemiological studies revealed that young children, in particular those who are malnourished, are highly susceptible to severe disease, and cryptosporidiosis is an important cause of early childhood mortality (2) as well as growth and development stunting (4–6). Vaccines and fully effective treatments are lacking.

Initially, a single species, *Cryptosporidium parvum*, was recognized in a wide range of mammals including humans (7). Extensive population genetic analysis (8) led to the current model of numerous species, subspecies, and strains (9). While these organisms have very similar genome sequences (10), they show profound phenotypic differences in host specificity (11), virulence (12), antigen repertoire (13, 14), and drug susceptibility (15), which impacts the epidemiology (16, 17), treatment, and prevention of the disease.

*Cryptosporidium* has a single-host, obligate sexual lifecycle, and sex is hypothesized to drive parasite adaption to new hosts, and changing environments (17–19). However, the true boundaries for sex and recombination within and between *Cryptosporidium* species are unknown, and our mechanistic understanding of gamete compatibility, fertilization, and meiosis is limited. Genetic crossing experiments have been attempted, but technical challenges in isolating and typing progeny limited the conclusions that could be drawn (20–22).

Here, we sought to develop a rigorous model for genetic crosses in *Cryptosporidium* by using drugs to isolate recombinant progeny to the exclusion of parental organisms. However, thus far, only a single drug-selectable marker was available for this organism, neomycin phosphotransferase (neo) which confers resistance to paromomycin (23). *Cryptosporidium* is naturally resistant to the inhibitors of protein, nucleotide, and folate synthesis used in other apicomplexans due to its highly reduced metabolism (23–25). The necessity to propagate the parasite in animals excludes many resistance genes due to the toxicity of the drugs used in their selection. We therefore turned our attention to

## Significance

The parasite *Cryptosporidium* is a leading cause of diarrheal disease. While infection is common worldwide, young children experiencing malnutrition are impacted most profoundly, and the disease is an important contributor to early childhood mortality. This study experimentally demonstrates that different strains and even species of *Cryptosporidium* can recombine their genomes through sex. The progeny of such genetic crosses show combined features of both parents, with resistance to multiple drugs being one example. Sex thus provides the opportunity to rapidly explore genetic space to provide progeny capable of surviving changing environments and hosts. Genetic crosses as an experimental tool may also be harnessed in the future to discover the genes underlying differences in virulence, drug sensitivity, and immunogenicity between parasite isolates.

Author contributions: S.S., G.X., B.M., and B.S. designed research; S.S., I.S.C., R.P.B., and F.A.-D. performed research; R.P.B., G.X., B.M., F.A.-D., and J.C.K. contributed new reagents/analytic tools; S.S., R.P.B., F.A.-D., J.C.K., and B.S. analyzed data; and S.S. and B.S. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

Copyright © 2023 the Author(s). Published by PNAS. This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

<sup>1</sup>To whom correspondence may be addressed. Email: striepen@upenn.edu.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2313210120/-DCSupplemental>.

Published December 26, 2023.


aminoacyl-tRNA synthetases, essential enzymes that have emerged as targets of anti-parasitic compounds (26–31). Among these, phenylalanyl tRNA synthetase (PheRS) was recently identified as a promising antimalarial target by phenotypic screening followed by genetic and biochemical validation studies (27, 32). The bicyclic azetidine BRD7929, an analog of the screening hits, was potent in multiple models of malaria. *Cryptosporidium* is susceptible to BRD7929 in vitro and in vivo, and a single-point mutation of the pheRS gene confers enhanced resistance (26). Building on this finding here, we design, test, and validate a dominant drug selection marker. We demonstrate that using mutated pheRS and neo as markers, recombinant progeny is readily isolated in genetic crossing experiments, and use this model to construct complex mutants and to explore the species boundaries of sex in *Cryptosporidium*.

## Results


**Mutation of *Cryptosporidium* pheRS Permits Selection for Transgenic Parasites.** *Cryptosporidium* modified to carry a mutation changing PheRS leucine 482 to valine showed enhanced resistance to BRD7929 (26). We hypothesized that this mutation could function as a dominant marker for transgenesis. We therefore engineered a template for homologous recombination to modify the endogenous pheRS locus that also introduces a nano luciferase/tdNeonGreen reporter cassette (Nluc/tdNG) (Fig. 1A). *C. parvum* sporozoites were electroporated with this construct along with a CRISPR/Cas9 plasmid targeting the pheRS locus (Fig. 1A). If  $\gamma^{-/-}$  mice infected with these parasites were treated with 10 mg/kg/day BRD7929. BRD7929 is not yet commercially available and we therefore synthesized 1 g of the compound; please refer to *SI Appendix, Figs. S1–S3* for detail on optimized synthesis

and documentation of structure and purity. Sustained luciferase activity was detectable in the feces of infected mice beginning on day 8 (Fig. 1B). Oocysts shed from day 9 to 17 were purified and subjected to flow cytometry, which showed green fluorescence in the transgenic parasites (pheRS<sup>r</sup>-Nluc-tdNG, Fig. 1C) but not in wild type (*Cp* WT, Fig. 1C). Genomic DNA was isolated from transgenic and wild-type oocysts and PCR mapping of the pheRS locus confirmed transgene integration (*SI Appendix, Fig. S4A*). Human colorectal (HCT-8) cells were infected and showed green fluorescent parasites at all time points and lifecycle stages observed (*SI Appendix, Fig. S4B*). We have since used this strategy numerous times and found it to reliably result in the isolation of stable transgenic organisms.

**A Mutated pheRS Gene Cassette Can Be Used as a Selection Marker In Trans.** Mutating the pheRS locus is suitable to introduce transgenes but does not allow modification of other positions in the genome. We thus asked whether introducing a mutated copy of the pheRS gene into a different locus would allow selection in trans. We engineered a construct that consisted of the entire pheRS gene including its promoter and the resistance mutation (Fig. 2A) and Nluc and targeted three dispensable loci that we previously successfully modified using the Neo marker. However, we only observed luciferase activity in one of these experiments targeting the thymidine kinase (*tk*) locus (23), and noted much lower luciferase reads than in previous experiments (Fig. 2B). We collected feces and infected a second group of mice, this time omitting BRD7929 treatment, and observed 100-fold higher luciferase activity in this second passage (*SI Appendix, Fig. S5A*). PCR mapping showed integration of the mutated pheRS version into the TK locus (*SI Appendix, Fig. S5B*) and amplicon sequencing demonstrated that only the transgenic copy



**Fig. 1.** PheRS can be used as a selection marker for stable transgenesis. (A) Map of the pheRS locus targeted by insertion of a construct that includes the single base mutation that confers resistance to BRD7929, nano luciferase (Nluc), and the fluorescent protein reporter tdNeonGreen. (B) If  $\gamma^{-/-}$  mice were infected with transfected parasites and burden was monitored by fecal luciferase activity. (C) Oocyst were purified from the feces and subjected to flow cytometry and transgenic parasites were highly fluorescent (gray: *Cp* WT; green: *Cp*-pheRS<sup>r</sup>-Nluc-tdNG).



**Fig. 2.** Using pheRS as selection marker in trans. (A) Map of the TK locus targeted by insertion of a construct that includes the pheRS gene (the last 113 bp were recodoned and carry the resistance mutation) and nano luciferase (Nluc). (B) Fecal luciferase activity from mice infected with parasites transfected using the transgene shown in A. (C) Parasite growth in HCT-8 cells assessed by measuring luminescence in the presence of the indicated concentrations of BRD7929. Means and SD of 3 biological replicates are shown; the entire experiment was conducted twice with similar results. (D and E) *Ifn $\gamma$ <sup>-/-</sup>* mice were infected with pheRS<sup>f</sup>-TK-KO (D) or pheRS<sup>WT</sup> (E), treated with the indicated doses of BRD7929 on days 4 to 8, and fecal nano luciferase activity was measured. (F) Parasites were transfected with construct shown in A. Infected *Ifn $\gamma$ <sup>-/-</sup>* mice were treated with 5 mpk BRD7929, and fecal nano luciferase activity was measured. (G) PCR mapping using genomic DNA from transgenic parasites selected in F demonstrating integration into the TK locus.

carried the resistance mutation, while the endogenous version was unchanged (SI Appendix, Fig. S5C). We conclude that pheRS can be used as a selection marker in trans to disrupt genes (pheRS<sup>f</sup>-TK-KO), but that the success rate appeared to be lower compared to modification of the endogenous locus.


We considered that pheRS modification in cis and trans might confer different levels of drug resistance. To test this, we compared the susceptibilities of the trans pheRS<sup>f</sup>-TK-KO (Fig. 2C, yellow), cis pheRS<sup>f</sup>-Nluc-tdNG (green), and pheRS<sup>WT</sup> (blue) selected with paromomycin. Sporozoites were used to infect HCT-8 cultures, and luciferase activity was measured after 48h over a range of BRD7929 concentrations (Fig. 2C). The IC<sub>50</sub> for pheRS<sup>WT</sup> was 56.5 nM and 1,028 nM for pheRS<sup>f</sup>-Nluc-tdNG, respectively, similar to values previously reported for BRD7929 resistant and

susceptible *C. parvum* (26). Interestingly, for the pheRS<sup>f</sup>-TK-KO strain, we determined an intermediate level of susceptibility (IC<sub>50</sub> = 462.7 nM). We also measured susceptibility in animals. *Ifn $\gamma$ <sup>-/-</sup>* mice were infected with the pheRS<sup>f</sup>-TK-KO strain and treated with 10 mg/kg, half that dose (5 mg/kg) to roughly match the difference in IC<sub>50</sub>, or carrier. Fecal luminescence measurements were normalized to the values measured on day 4 when treatment was initiated (Fig. 2D). Mice treated with the half dose showed values similar to untreated mice (Fig. 2D), treatment with 10 mg/kg resulted in reduced shedding. Both doses were equally effective in curing mice infected with pheRS<sup>WT</sup> (Fig. 2E). We conclude that introducing the pheRS<sup>f</sup> marker in trans confers resistance, yet at a lower level. We therefore conducted transfection experiments employing BRD7929 dosing reduced to half and found

that transgenic parasites were readily isolated with a parasite burden matching those seen when modifying pheRS in cis, or using Neo and paromomycin (Fig. 2 F and G).

**Drug Selection Enables Genetic Cross and Isolation of Recombinant Progeny in *C. parvum*.** Genetic exchange by sex has been reported for *Cryptosporidium* (33), but isolating recombinant progeny has been difficult. We therefore tested whether parasites resistant to different drugs can be crossed using a dual selection

protocol. We constructed *C. parvum* strains with complementary drug markers, and fluorescent reporters: one BRD7929 resistant and green fluorescent (*Cp*-pheRS<sup>r</sup>-Nluc-tdNG), the other paromomycin resistant and red (*Cp*-Paro<sup>r</sup>-tdTom) (Fig. 3A). Both strains carried the luciferase reporter to track the infection. Ifn $\gamma$ <sup>-/-</sup> mice were infected with each strain individually or with both, and treatment with paromomycin and BRD7929 was initiated after 4 d (Fig. 3B). Mice infected with individual strains were cured by this treatment within 4 d (Fig. 3C and D), and infection



**Fig. 3.** Establishment of highly efficient crosses in *Cryptosporidium*. (A) Maps of the loci used to mark each of the parental *C. parvum* lines. (B) Experimental set-up of the crossing experiment between pheRS<sup>r</sup>-Nluc-tdNG which is susceptible to BRD7929 and expresses tdNeonGreen and Paro<sup>r</sup>-tdTom which is susceptible to paromomycin and expresses tdTomato. (C-E) Ifn $\gamma$ <sup>-/-</sup> mice were infected with the indicated parasite strains, subjected to dual drug treatment, and parasite burden was measured by fecal luciferase assay. Note that single infected mice are cured while co-infected mice remain infected. BRD7929 treatment was stopped on day 8, paromomycin treatment was continued until the end of the experiment. (F-H) Flow cytometric analysis of oocysts isolated from E at the days indicated (days 11 and 14 were indistinguishable from ref. 8, see SI Appendix, Fig. S6 A and B). F shows a mixture of both parental strains. (I) PCR mapping of the marked TK and pheRS loci in the parental lines and the cross (numbers indicate primer pairs highlighted in A). Note that the progeny of the cross is recombinant and inherited markers and reporters from both parents.

did not relapse when the drug treatment ended on day 8. In contrast, mice co-infected with both strains showed continued heavy shedding (Fig. 3E). We conclude that parasites, carrying a single marker, are fully susceptible to the drug cocktail, and that coinfection produced double-drug resistance, suggesting successful recombination and cross.

We next used fluorescence to phenotype the progeny at the single-oocyst level. Oocysts were purified from the feces and subjected to flow cytometry on days 4 and 8. Parental parasites were used to establish strain-specific cytometry gates, and we found exclusive staining of each strain (Fig. 3F). On day 4 of co-infection, we observed red, green, and importantly, double positive oocysts (Fig. 3G), which accounted for roughly half of the recorded events. Following the impact of treatment, we observed uniform red and green fluorescence (Fig. 3H and *SI Appendix, Fig. S6 A and B*). We note populations displaying intermediate fluorescence for either red or green on day 4 that are subsequently lost during selection (*Discussion*). When we PCR amplified transgenes using diagnostic primer pairs in the parental strains, single amplicons were detected in a strain-specific fashion; however, when using oocyst selected in crosses, both amplicons were present (Fig. 3I). We repeated this genetic cross with a similar outcome and thus conclude that applying the pressure of two drugs results in the selection of recombinant progeny to the exclusion of the parental strains.

#### Sexual Cross Permits Isolation of Conditionally Lethal Mutants.


The ease and efficiency of recombination led us to ask whether crosses may enable more complex genetic manipulations in *C. parvum*. We recently demonstrated the use of dimerizable Cre recombinase (DiCre) for rapamycin induced gene ablation; however, introducing loxP sites and recombinase in a single transfection is challenging (see extended technical discussion in ref. 34). To overcome this, we devised a model in which we cross a Cre driver and a floxed strain (Fig. 4A). We generated DiCre-expressing parasites using BRD7929 selection (pHeRS<sup>-</sup>-Nluc-DiCre, Fig. 4A and *SI Appendix, Fig. S7A*), and a color switch reporter line (loxP-tdTom-loxP-tdNeon-Nluc-Paro<sup>r</sup>, Fig. 4A and *SI Appendix, Fig. S7A*) using paromomycin selection. Introns harboring loxP sites were placed to allow Cre-mediated excision of the red marker to activate the green. The strains were crossed as described (Fig. 3A), and purified oocysts were used to infect HCT-8 cells. After 3 d, genomic DNA was isolated, and the floxed gene was amplified by PCR. Rapamycin treatment led to loss of the large amplicon and concomitant accumulation of a smaller molecule (Fig. 4B) consistent with Cre-mediated excision. We also noted some leaky Cre activity in the absence of rapamycin as previously described (34). Infected cultures grown in the presence or absence of rapamycin for 48 h, were fixed and imaged. Parasites not exposed to rapamycin expressed tdTomato, while those exposed to rapamycin expressed tdNeonGreen (Fig. 4C), and we quantified this switch using flow cytometry (Fig. 4D).

We next engineered a strain that carried a floxed drug resistance cassette (*Cp*-Nluc-loxP-Paro<sup>r</sup>-loxP, Fig. 4A and *SI Appendix, Fig. S7 A and B*). This strain was again crossed with the DiCre driver and recombinant progeny was isolated. HCT-8 cells infected with these parasites were incubated in the presence or absence of rapamycin, and diagnostic PCR showed progressive excision under rapamycin (*SI Appendix, Fig. S7C*). To test the functional consequence of treatment we turned to in vivo experiments. Two groups of Ifn $\gamma$ <sup>-/-</sup> mice were infected with the progeny, and all animals were treated with paromomycin. One group was also treated with rapamycin (10 mg/kg/day by gavage). PCR of the floxed locus demonstrated

efficient rapamycin-dependent excision in vivo (Fig. 4E). Following fecal luminescence, we observed robust infection in the vehicle-treated group, confirming the progeny's resistance to paromomycin. In contrast, mice receiving rapamycin showed dramatic reduction of parasite burden (Fig. 4F). We conclude that sexual cross permits modification of multiple independent loci and that applying this system to gene deletion results in conditional mutants allowing the study of essential genes in vivo.

**Testing the Boundaries of Genetic Exchange between *Cryptosporidium* Species.** Numerous species of *Cryptosporidium* have been described largely defined by ecological isolation through host specificity (19), reflected in names like *Cryptosporidium hominis*, *Cryptosporidium meleagridis*, or *Cryptosporidium canis*. Whether they are reproductively isolated, is unknown, but of great epidemiological importance (23, 33, 35). We sought to test the species barrier experimentally using *C. parvum* and *Cryptosporidium tyzzeri*, two species with 95% identical genome sequence (36–38). *C. tyzzeri* naturally infects mice, and *C. parvum* cattle and humans, however, both can infect mice lacking interferon  $\gamma$ . We therefore engineered *C. tyzzeri* strain STL [(39), a kind gift from Dr. Chyi-Song Hsieh] to express red fluorescent protein using paromomycin selection (optimized dose of 32 g/L, *Ct* Paro<sup>r</sup>-Nluc-tdTom, *SI Appendix, Fig. S8A*). PCR demonstrated transgenesis (*SI Appendix, Fig. S8B*), and purified oocysts showed homogenous red fluorescence (*SI Appendix, Fig. S8C*).

We next co-infected Ifn $\gamma$ <sup>-/-</sup> mice with 2,000 oocysts of *Ct* Paro<sup>r</sup>-Nluc-tdTom and 8,000 oocysts of *Cp* pheRS<sup>-</sup>-Nluc-tdNG and initiated dual drug selection on day 4 (we biased the inoculum toward *C. parvum* to balance *C. tyzzeri*'s superior ability to infect mice). Parasite burden rapidly declined upon treatment (Fig. 5A), however, rebounded and increased to 100-fold by day 21, indicating the emergence of dual drug resistance. When analyzed by flow cytometry the parents were either red or green (Fig. 5B). In contrast, oocyst isolated on day 21 of coinfection were exclusively double positive (Fig. 5C). We amplified segments of the progeny's genome carrying the resistance markers as well as the 18S and *gp60* loci, both commonly used in genotyping (40, 41). Sequencing these amplicons revealed *C. tyzzeri*-specific SNPs in TK and *gp60* and *C. parvum*-specific sequences in the PheRS and 18S loci (Fig. 5D). To test this genome-wide, we conducted whole genome sequencing of both parents and the progeny and obtained ~75 fold coverage for the progeny (Fig. 5E). The *Cp* parent is near identical to the *C. parvum* reference genome (868 SNPs), while the *Ct* parent shows 186,218 SNPs. In Fig. 5F, the relative frequency of these *Ct* SNPs across all eight chromosomes of the progeny are plotted. This showed interspecies recombination for multiple chromosomes. The nanopore bulk sequencing shows that some chromosomes are largely derived from a single parent, and this is particularly noticeable (but not exclusive) for those chromosomes carrying the selection marker (3 for *Cp* and 5 for *Ct*). We also obtained long-read sequence for smaller portions of the genome from single oocysts isolated by flow cytometry; it is currently impractical to clone this organism. As one example on chromosome 8, we find sequences from both parents, and bridging cross-over points were supported by hundreds of long reads (Fig. 5G and *SI Appendix, Fig. S9*). *SI Appendix, Fig. S10* shows a more detailed comparison of bulk and single oocyst genome sequences for chromosomes 2, 5, and 4, contrasting preferential inheritance from a single parent with balanced ancestry, respectively. Zooming in to even higher resolution *SI Appendix, Fig. S11* shows diversity among single oocysts and numerous apparent cross-over sites. To which degree these patterns reflect meiotic cross-over or meiotic gene



**Fig. 4.** Conditional gene ablation in crossed progeny. (A) Illustration of the experimental set-up crossing a Cre driver with floxed strains and the respective phenotypic assays for gene excision. (B–D) Progeny of the loxP-tdTom-loxP-tdNeon-Nluc-Paro<sup>+</sup> color switch cross was used to infect HCT-8 cells and cultures were treated with rapamycin (Rapa). (B) Genomic DNA was extracted from oocysts (cross) or from cultures infected for 3 d, and the floxed gene was amplified by PCR. Amplicons are 2,076 bp for the floxed, and 467 bp for the excised locus, respectively. (C) Representative micrographs of HCT-8 cells infected with cross progeny after 48 h with or without rapamycin. (Scale bar, 5  $\mu$ m.) (D) HCT-8 cells infected with cross progeny were analyzed by flow cytometry after 72 h of rapamycin treatment and relative transgene expression is plotted as their portions of total fluorescent cells. Means and SDs of three biological replicates are shown. (E and F) Ifn $\gamma$ <sup>-/-</sup> mice were infected with progeny of the cross between the DiCre and Cp-loxP-Paro<sup>+</sup>-loxP strains. (E) Ifn $\gamma$ <sup>-/-</sup> mice infected with the progeny of a cross between the DiCre and Cp-loxP-Paro<sup>+</sup>-loxP lines, treated with rapamycin or vehicle, and genomic DNA was extracted from the feces at the indicated times. PCR analysis revealed amplicons for the floxed (1,269 bp) and excised locus (432 bp), respectively. Note strong rapamycin dependent induction. (F) Fecal nano luciferase measurements from these mice revealed paromomycin susceptibility as a consequence of in vivo Cre-mediated excision induced by rapamycin.


conversion repair events requires further study, and they may be the product of both.

## Discussion

Parasitism is one of the most powerful ecological drivers of speciation and parasites like braconid wasps, mites, or apicomplexans are among the most species-rich eukaryotic taxa (42, 43). The host–parasite arms race of restriction and evasion results in diversifying evolution and favors the emergence of host specificity (44). In turn, host specificity provides isolation by habitat, further accelerating speciation. This is evident in the genus *Cryptosporidium*

where numerous different species and strains infect a variety of animals (45). *C. parvum*, one of the most important and best-studied species, alone comprises at least 20 subtypes (46), some appear in the process of speciation by adaptation to humans as exclusive host (47). Species boundaries are also maintained by reproductive isolation. What role such sexual incompatibility plays for parasites is largely unknown, but is an important question, as sexual recombination can result in hypervirulence and global expansion of new strains as documented for, e.g., *Toxoplasma gondii* (48).

Here, we develop an experimental model for genetic crosses in *C. parvum* in mice to study parasite sex. Using fluorescent parents,



**Fig. 5.** Testing the species boundaries of genetic exchange in *Cryptosporidium*. (A)  $\text{Ifn}\gamma^{-/-}$  mice were infected with *C. parvum* pheRS<sup>-</sup>-Nluc-tdNG and *C. tyzzeri* Paro<sup>-</sup>-tdTom and subjected to dual drug treatment over the time indicated by shading in yellow. Parasite burden was measured by the fecal nano luciferase assay. (B) Flow cytometry of a mixture of both parental oocysts, and (C), oocyst isolated on day 21 (arrow in A) following coinfection showing uniform double positive fluorescence. (D) The indicated loci were amplified by PCR from day 21 progeny oocysts, and amplicons were subjected to Sanger sequencing. Amplicons were genotyped using species-specific SNPs. *C. tyzzeri* SNPs are shown in red, those specific for *C. parvum* in green. Agarose gel shows the fragments that were sent in for sequencing. Red and green lines depict SNPs between *C. parvum* and *C. tyzzeri*. (E) Coverage of nanopore reads of the cross. The red line indicates median coverage for each chromosome. (F) Calculation of the common *C. tyzzeri* SNP position and frequency obtained from bulk sequencing of the crossed progeny plotted across all 8 chromosomes. (G) Progeny was also subjected to single-oocyst sequencing and a recombinant locus on chromosome 8 is depicted. The colors in the read coverage plot represent the nucleotide of SNPs, with adenine in green, cytosine in blue, guanine in yellow, and thymine in red (see *SI Appendix, Fig. S9* for a multiple sequence alignment of long reads at this locus) and *SI Appendix* alignment of 50 randomly selected reads.

we show evidence of robust recombination by flow cytometry. Interestingly, early in infection, we observed oocysts with different fluorescence levels, which likely reflects maternal cytoplasmic inheritance (*SI Appendix, Fig. S12*). The female gamete is much larger and responsible for the bulk of the oocyst proteome (35, 49). In the first cross, maternal fluorescence thus outweighs the male, following selection both parents are double positive, yielding uniform highly fluorescent progeny. Highly fluorescent oocysts therefore are the product of at least two subsequent crosses, indicating that 4 d into the infection, some parasites already ran through their lifecycle twice. This may appear fast but matches the compact 48 h lifecycle recently established by time lapse microscopy (50). Using two mechanisms of drug resistance selects for recombinant progeny to the exclusion of their parents. This is very efficient, underscoring that *Cryptosporidium* oocysts are indeed autoinfective and continuously reset the lifecycle sustaining infection. This differs from other well-studied apicomplexans where infection is sustained by the continuous replication of an asexual form and sexual differentiation is linked to transmission to the next host (51).

Progeny are readily observed when crossing *C. parvum* strains, and maybe surprisingly, also when pairing *C. parvum* with a different species, *C. tyzzeri*. We rigorously documented genetic exchange using measurements of drug resistance, fluorescent protein expression, PCR mapping, and whole genome sequencing, which demonstrated the presence of SNPs from both species on the same DNA molecule. We conclude that, using selection and a host susceptible to both species [we used  $\text{Ifn}\gamma^{-/-}$  mice here (38, 52)], the species barrier can be breached. Not all chromosomes showed equal levels of recombination and further studies are needed to determine whether this reflects strong selection (e.g., due to the presence of the marker) or local meiotic incompatibilities. Overall, our findings suggest that the current species concept and taxonomy rests largely on ecological and not reproductive isolation.

The availability of a second selection marker and the ease of crossing now permits modification or ablation of multiple loci. Crossing floxed parasites with Cre driver strains, resulted in highly penetrant conditional gene ablation, a critical tool to dissect essential phenomena in a haploid organism. Rapamycin induction can be used in vivo in animals, which is of particular interest for *Cryptosporidium*, where

not all aspects of parasite biology are well modeled in tissue culture. Numerous additional methods have been developed to study essential genes in apicomplexans, allowing for ablation or modulation at the gene, transcript, or protein level, each with their own relative strengths and weaknesses (53). Most importantly, however, the model reported here enables forward genetic studies in *Cryptosporidium*. Genetic mapping revealed mechanisms of drug resistance and virulence in *Plasmodium* (54, 55) and *Toxoplasma* (56–59). Currently, it is not practical to clone individual progeny of *Cryptosporidium* crosses. However, bulk segregant analysis to map quantitative trait loci is well suited to this parasite, please refer to ref. 60 for a thoughtful review of recent technological advances. *Cryptosporidium* is well suited to this approach: It has a small genome, follows Mendelian rules of inheritance (33, 61), and strains that differ in host specificity, virulence, and drug susceptibility have been reported (12, 15, 62) that lend themselves to build the selection component inherent to quantitative trait mapping by bulk segregant analysis. Much of the biology of *Cryptosporidium* remains poorly understood, we expect the use of genetic crosses to discover gene function by mapping to be transformative.

## Materials and Methods

**Parasites and Mice.** *C. parvum* Iowa II (IIa) strain oocysts were obtained from Bunch Grass Farms. A *C. tyzzeri* strain isolated from laboratory mice at Washington University in St. Louis was kindly provided by Dr. Chyi-Song Hsieh, University of Washington (39). Parasites were maintained in 6- to 8-wk-old male and female *Irfn<sup>-/-</sup>* (Jackson Laboratory stock no. 002287) or C57BL/6 (Ct) mice bred in-house. Six- to eight-week-old mice were treated with antibiotics and infected as detailed in ref. 23. Feces were collected from each mouse and mixed, and 20 mg were used to measure parasite burden by luciferase assay.

**Generation of Transgenic Parasites.** Guide oligonucleotides (Sigma-Aldrich) were introduced into the *C. parvum* Cas9/U6 plasmid (23) by restriction cloning (see ref. 63 for guide design) and repair templates were constructed by Gibson assembly (New England Biolabs). Excysted sporozoites were transfected as described (63). Details on the transgenic strains generated in this study can be found in *SI Appendix*.

To generate transgenic parasites,  $5 \times 10^7$  oocysts were incubated at 37 °C for 1 h in 10 mM HCl followed by two washes with phosphate buffered saline (PBS) and an incubation at 37 °C for 1 h in 0.2 mM sodium taurocholate and 22 mM sodium bicarbonate to induce excystation (64). Excysted sporozoites were electroporated and used to infect mice as described in ref. 63. Integration was evaluated by PCR using primers detailed in *SI Appendix, Table S2*.

**Cell Culture and Microscopy.** HCT-8 cells were purchased from ATCC (CCL-224TM) and maintained in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% Cosmic calf serum (HyClone). Cells were infected with bleached and

washed oocysts and serum was reduced to 1%. Infected cells were fixed with 4% paraformaldehyde (Electron Microscopy Science) in PBS and stained with Hoechst (1 µg/mL). Coverslips were then mounted on glass slides with fluorogel (Electron Microscopy Science) mounting medium.

***Cryptosporidium* In Vitro Drug Assays and IC<sub>50</sub> Determination.** HCT-8 cells were infected with 1,000 oocysts per well and incubated with drug. Medium was aspirated after 48 h, cells were lysed and mixed with NanoGlo substrate (Promega) and luminescence was measured using a Glomax reader (Promega) (63). IC<sub>50</sub> values were calculated in GraphPad Prism software v9 (two experiments, each conducted with triplicate wells).

**Rapamycin Treatment.** Rapamycin (LC Laboratories) was dissolved in 95% ethanol (50 mg/mL stock). Mice were weighed and treated daily by oral gavage with 100 µL of drug solution adjusted with water to deliver 10 mg/kg body weight.

**Flow Cytometry.** Oocysts were enriched using a miniaturized sucrose floatation of feces from infected mice (see *SI Appendix* for a detailed protocol), resuspended in fluorescence activated cell sorting (FACS) buffer (1 × PBS, 0.2% bovine serum albumin, 1 mM ethylenediaminetetraacetic acid). Infected HCT8 cells were trypsinized, washed in FACS buffer, blocked (99.5% FACS Buffer, 0.5% normal rat IgG, 1 µg/mL 2.4G2), washed, and stained with Hoechst (1 µg/mL) on ice. All samples were passed through a 35 µm filter prior to flow cytometry using a LSRFortessa or FACSymphony A3 Lite and analyzed with FlowJo v10 software (TreeStar).

**Genome Sequencing.** DNA extraction, sequencing, and computational analyses including variant mapping are detailed in *SI Appendix*. In brief, 150-bp paired-end Illumina sequencing was used for parental strains, cross-progeny were subjected to multiple displacement amplification and Oxford Nanopore sequencing.

**Data, Materials, and Software Availability.** Raw sequence read data can be obtained from NCBI BioProject [PRJNA1000584](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1000584) (65) and BioSamples [SAMN36772387](https://www.ncbi.nlm.nih.gov/biosamples/SAMN36772387), [SAMN36772388](https://www.ncbi.nlm.nih.gov/biosamples/SAMN36772388), and [SAMN36772389](https://www.ncbi.nlm.nih.gov/biosamples/SAMN36772389).

**ACKNOWLEDGMENTS.** This work was supported in part by the NIH with grants to B.S. (R01AI112427 and R01AI127798), J.C.K. and Travis Glenn (R01AI148667), a fellowship to I.S.C. (F30AI169744), support to F.A.-D. (T32GM142623), and fellowships from the Swiss NSF to S.S. (P2BEP3\_191774 and P500PB\_211097). We thank Chyi Hsieh for sharing *C. tyzzeri* oocysts, and Abhijit Kundu (TCGLS) for small molecule synthesis, and Travis Glenn for help with single oocyst sequencing and mentorship of F.A.-D.

Author affiliations: <sup>a</sup>Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104; <sup>b</sup>Department of Medicine, Houston Methodist Research Institute, Houston, TX 77030; <sup>c</sup>Department of Chemistry, Scripps Research, La Jolla, CA 92037; <sup>d</sup>Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA 02142; <sup>e</sup>Department of Genetics, University of Georgia, Athens, GA 30602; and <sup>f</sup>Center for Tropical and Emerging Global Diseases and Institute of Bioinformatics, University of Georgia, Athens, GA 30602

1. K. L. Kotloff, The burden and etiology of diarrheal illness in developing countries. *Pediatr. Clin. North Am.* **64**, 799–814 (2017).
2. K. L. Kotloff *et al.*, Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. *Lancet (London, England)* **382**, 209–222 (2013).
3. I. S. Cohn *et al.*, Immunity to *Cryptosporidium*: Lessons from acquired and primary immunodeficiencies. *J. Immunol.* **209**, 2261–2268 (2022).
4. W. Checkley *et al.*, A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for *Cryptosporidium*. *Lancet. Infect. Dis.* **15**, 85–94 (2015).
5. R. M. O'Connor *et al.*, *Cryptosporidiosis* in patients with HIV/AIDS. *AIDS* **25**, 549–560 (2011).
6. B. Striepen, Parasitic infections: Time to tackle *cryptosporidiosis*. *Nature* **503**, 189–191 (2013).
7. S. Tzipori *et al.*, *Cryptosporidium*: Evidence for a single-species genus. *Infect. Immun.* **30**, 884–886 (1980).
8. G. Widmer, Genetic heterogeneity and PCR detection of *Cryptosporidium parvum*. *Adv. Parasitol.* **40**, 223–239 (1998).
9. Y. Guo *et al.*, Emergence of zoonotic *Cryptosporidium parvum* in China. *Trends Parasitol.* **38**, 335–343 (2022).
10. R. P. Baptista *et al.*, Long-read assembly and comparative evidence-based reanalysis of *Cryptosporidium* genome sequences reveal expanded transporter repertoire and duplication of entire chromosome ends including subtelomeric regions. *Genome Res.* **32**, 203–213 (2022).
11. U. Ryan *et al.*, An update on zoonotic *Cryptosporidium* species and genotypes in humans. *Animals (Basel)* **11**, 3307 (2021).
12. R. Jia *et al.*, High infectivity and unique genomic sequence characteristics of *Cryptosporidium parvum* in China. *PLoS Negl. Trop. Dis.* **16**, e0010714 (2022).
13. A. Sheoran *et al.*, Infection with *Cryptosporidium hominis* provides incomplete protection of the host against *Cryptosporidium parvum*. *J. Infect. Dis.* **205**, 1019–1023 (2012).
14. A. Sheoran *et al.*, Pregnant sows immunized with *Cryptosporidium parvum* significantly reduced infection in newborn piglets challenged with *C. parvum* but not with *C. hominis*. *PLoS Negl. Trop. Dis.* **16**, e0010690 (2022).
15. M. S. Love *et al.*, A high-throughput phenotypic screen identifies clofazimine as a potential treatment for *cryptosporidiosis*. *PLoS Negl. Trop. Dis.* **11**, e0005373 (2017).
16. W. Huang *et al.*, Multiple introductions and recombination events underlie the emergence of a hyper-transmissible *Cryptosporidium hominis* subtype in the USA. *Cell Host Microbe* **31**, 112–123.e4 (2022), 10.1016/j.chom.2022.11.013.
17. S. Tichkule *et al.*, Global population genomics of two subspecies of *Cryptosporidium hominis* during 500 years of evolution. *Mol. Biol. Evol.* **39**, msac056 (2022).
18. A. R. Jex, K. M. Tyler, American variants of *Cryptosporidium hominis*: Over-sexed and over here? *Cell Host Microbe* **31**, 5–7 (2023).
19. W. Huang *et al.*, Multiple introductions and recombination events underlie the emergence of a hyper-transmissible *Cryptosporidium hominis* subtype in the USA. *Cell Host Microbe* **31**, 112–123.e4 (2023).
20. Y. Guo *et al.*, Comparative genomic analysis reveals occurrence of genetic recombination in virulent *Cryptosporidium hominis* subtypes and telomeric gene duplications in *Cryptosporidium parvum*. *BMC Genom.* **16**, 320 (2015).



21. S. Tanriverdi *et al.*, Genetic crosses in the apicomplexan parasite *Cryptosporidium parvum* define recombination parameters. *Mol. Microbiol.* **63**, 1432–1439 (2007).
22. X. Feng *et al.*, Experimental evidence for genetic recombination in the opportunistic pathogen *Cryptosporidium parvum*. *Mol. Biochem. Parasitol.* **119**, 55–62 (2002).
23. S. Vinayak *et al.*, Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. *Nature* **523**, 477–480 (2015).
24. M. C. Pawlowic *et al.*, Genetic ablation of purine salvage in *Cryptosporidium parvum* reveals nucleotide uptake from the host cell. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 21160–21165 (2019).
25. M. S. Abrahamson *et al.*, Complete genome sequence of the apicomplexan, *Cryptosporidium parvum*. *Science* **304**, 441–445 (2004).
26. S. Vinayak *et al.*, Bicyclic azetidines kill the diarrheal pathogen *Cryptosporidium* in mice by inhibiting parasite phenylalanyl-tRNA synthetase. *Sci. Transl. Med.* **12**, eaba8412 (2020).
27. N. Kato *et al.*, Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. *Nature* **538**, 344–349 (2016).
28. T. Hussain *et al.*, Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases. *Antimicrob. Agents Chemother.* **59**, 1856–1867 (2015).
29. D. Hoepfner *et al.*, Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. *Cell Host Microbe* **11**, 654–663 (2012).
30. J. D. Herman *et al.*, The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. *Sci. Transl. Med.* **7**, 288ra77 (2015).
31. B. Baragaña *et al.*, Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 7015–7020 (2019).
32. C. J. Gerry, S. L. Schreiber, Chemical probes and drug leads from advances in synthetic planning and methodology. *Nat. Rev. Drug Discov.* **17**, 333–352 (2018).
33. G. Wilke *et al.*, A stem-cell-derived platform enables complete *Cryptosporidium* development in vitro and genetic tractability. *Cell Host Microbe* **26**, 123–134.e8 (2019).
34. J. Tandel *et al.*, Genetic ablation of a female-specific ap2 transcription factor blocks oocyst shedding in *Cryptosporidium parvum*. *MBio* **14**, e0326122 (2023), 10.1128/mbio.03261-22.
35. J. Tandel *et al.*, Life cycle progression and sexual development of the apicomplexan parasite *Cryptosporidium parvum*. *Nat. Microbiol.* **4**, 2226–2236 (2019).
36. X. Ren *et al.*, *Cryptosporidium tyzzeri* n. sp. (Apicomplexa: Cryptosporidiidae) in domestic mice (*Mus musculus*). *Exp. Parasitol.* **130**, 274–281 (2012).
37. M. Kváč *et al.*, Coevolution of *Cryptosporidium tyzzeri* and the house mouse (*Mus musculus*). *Int. J. Parasitol.* **43**, 805–817 (2013).
38. A. Sateriale *et al.*, A genetically tractable, natural mouse model of cryptosporidiosis offers insights into host protective immunity. *Cell Host Microbe* **26**, 135–146.e5 (2019).
39. E. V. Russler-Germain *et al.*, Commensal *Cryptosporidium* colonization elicits a cDC1-dependent Th1 response that promotes intestinal homeostasis and limits other infections. *Immunity* **54**, 2547–2564.e7 (2021).
40. S. Glaberman *et al.*, Three drinking-water-associated cryptosporidiosis outbreaks, Northern Ireland. *Emerg. Infect. Dis.* **8**, 631–633 (2002).
41. J. Šlapeta, *Cryptosporidium*: Identification and genetic typing. *Curr. Protoc. Microbiol.* **44**, 20B.1.1–20B.1.17 (2017).
42. A. A. Forbes *et al.*, Quantifying the unquantifiable: Why Hymenoptera, not Coleoptera, is the most speciose animal order. *BMC Ecol.* **18**, 21 (2018).
43. B. B. Larsen *et al.*, Inordinate fondness multiplied and redistributed: The number of species on earth and the new pie of life. *Q. Rev. Biol.* **92**, 229–265 (2017).
44. M. A. Brockhurst *et al.*, Running with the Red Queen: The role of biotic conflicts in evolution. *Proc. R. Soc. B* **281**, 20141382 (2014).
45. J. Šlapeta, Cryptosporidiosis and *Cryptosporidium* species in animals and humans: A thirty colour rainbow? *Int. J. Parasitol.* **43**, 957–970 (2013).
46. Y. Feng *et al.*, Genetic diversity and population structure of *Cryptosporidium*. *Trends Parasitol.* **34**, 997–1011 (2018).
47. J. L. Nader *et al.*, Evolutionary genomics of anthroponosis in *Cryptosporidium*. *Nat. Microbiol.* **4**, 826–836 (2019).
48. M. E. Grigg *et al.*, Success and virulence in *Toxoplasma* as the result of sexual recombination between two distinct ancestries. *Science* **294**, 161–165 (2001).
49. A. Guérin *et al.*, *Cryptosporidium* uses multiple distinct secretory organelles to interact with and modify its host cell. *Cell Host Microbe* **31**, 650–664.e6 (2023).
50. E. D. English *et al.*, Live imaging of the *Cryptosporidium parvum* life cycle reveals direct development of male and female gametes from type I meronts. *PLoS Biol.* **20**, e3001604 (2022).
51. S. Lourido, *Toxoplasma gondii*. *Trends Parasitol.* **35**, 944–945 (2019).
52. J. K. Griffiths *et al.*, The gamma interferon gene knockout mouse: A highly sensitive model for evaluation of therapeutic agents against *Cryptosporidium parvum*. *J. Clin. Microbiol.* **36**, 2503–2508 (1998).
53. J. C. Hanna *et al.*, Mode of action studies confirm on-target engagement of lysyl-tRNA synthetase inhibitor and lead to new selection marker for *Cryptosporidium*. *Front. Cell. Infect. Microbiol.* **13**, 1236814 (2023).
54. T. E. Wellems *et al.*, Chloroquine resistance not linked to *mdr*-like genes in a *Plasmodium falciparum* cross. *Nature* **345**, 253–255 (1990).
55. D. A. Fidock *et al.*, Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol. Cell* **6**, 861–871 (2000).
56. M. S. Behnke *et al.*, Rhopty proteins ROP5 and ROP18 are major murine virulence factors in genetically divergent South American strains of *Toxoplasma gondii*. *PLoS Genet.* **11**, e1005434 (2015).
57. M. S. Behnke *et al.*, Genetic mapping of pathogenesis determinants in *Toxoplasma gondii*. *Annu. Rev. Microbiol.* **70**, 63–81 (2016).
58. J. P. J. Saeij *et al.*, Polymorphic secreted kinases are key virulence factors in toxoplasmosis. *Science* **314**, 1780–1783 (2006).
59. S. Taylor *et al.*, A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen *Toxoplasma gondii*. *Science* **314**, 1776–1780 (2006).
60. X. Li *et al.*, Bulk segregant linkage mapping for rodent and human malaria parasites. *Parasitol. Int.* **91**, 102653 (2022).
61. P. Xu *et al.*, The genome of *Cryptosporidium hominis*. *Nature* **431**, 1107–1112 (2004).
62. X. He *et al.*, A productive immunocompetent mouse model of cryptosporidiosis with long oocyst shedding duration for immunological studies. *J. Infect.* **84**, 710–721 (2022).
63. M. C. Pawlowic *et al.*, Generating and maintaining transgenic *Cryptosporidium parvum* parasites. *Curr. Protoc. Microbiol.* **46**, 20B.2.1–20B.2.32 (2017).
64. S. Kato *et al.*, Chemical and physical factors affecting the excystation of *Cryptosporidium parvum* oocysts. *J. Parasitol.* **87**, 575–581 (2001).
65. S. Shaw, B. Striepen, Genetic crosses between species of *Cryptosporidium*. National Center for Biotechnology Information, GenBank Bioproject. <https://www.ncbi.nlm.nih.gov/bioproject/?term=PRAJNA+1000584>. Deposited 31 July 2023.